文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

全身免疫炎症指数预测直接经皮冠状动脉介入治疗后无复流现象。

Systemic immune-inflammation index predicts no-reflow phenomenon after primary percutaneous coronary intervention.

机构信息

aDepartment of Cardiology, Ankara University Faculty of Medicine, Ankara, Turkey.

bDepartment of Cardiology, Hatay Mustafa Kemal University Faculty of Medicine, Hatay, Turkey.

出版信息

Acta Cardiol. 2022 Feb;77(1):59-65. doi: 10.1080/00015385.2021.1884786. Epub 2021 Feb 22.


DOI:10.1080/00015385.2021.1884786
PMID:33612077
Abstract

OBJECTIVE: Systemic immune-inflammation index (SII), on the basis of lymphocyte, neutrophil and platelet counts had been published to be a good prognostic factor in coronary artery disease. Nevertheless, the prognostic value of Systemic immune-inflammation index (SII) in a condition of no-reflow phenomenon (NRP) remains inconsistent, we evaluated the SII as a simple calculated tool for predicting the NRP among patients with STEMI who underwent primary percutaneus coronary intervention (PCI). METHOD: 510 consecutive acute STEMI patients who underwent primary PCI within 12 h from symptom onset from October 2015 to January 2020 were enrolled in our study. The receiver-operating characteristic (ROC) curve was used to determine the cut-off value of SII to predict the no-reflow. Multivariate stepwise logistic regression, including covariates found to have a significant association with NRP in univariate analysis, was used to identify independent predictors of no-reflow. RESULTS: A ROC curve analysis showed that the best cut-off value of SII for predicting no-reflow was 1028, with sensitivity and specificity of 79% and 70, respectively (AUC, 0.839; 95% CI 0.797-0.881). An ROC curve comparison analysis was performed to compare the SII with NLR and PLR. Multivariate analysis revealed that SII ≥1028 value (OR = 6.622, 95% confidence interval (CI): 3.802-11.627,  < .001), not using aspirin prior to admission (OR = 0.431, 95%CI: 0.236-0.786,  = .006), and CRP (OR = 1.004, 95%CI: 1.001-1.008,  = .041) were independent predictors related to occurrence of NRP after primary PCI in patients with acute STEMI. CONCLUSION: SII levels are independently associated with the NRP in patients undergoing primary PCI for acute STEMI. High SII may be a promising indicator for the prediction of NRP in these patients.

摘要

目的:基于淋巴细胞、中性粒细胞和血小板计数的全身免疫炎症指数(SII)已被发表为冠心病的一个良好预后因素。然而,SII 在无复流现象(NRP)情况下的预后价值仍然不一致,我们评估了 SII 作为一种简单的计算工具,用于预测接受直接经皮冠状动脉介入治疗(PCI)的急性 ST 段抬高型心肌梗死(STEMI)患者的 NRP。

方法:本研究纳入了 2015 年 10 月至 2020 年 1 月期间症状发作后 12 小时内接受直接 PCI 的 510 例连续急性 STEMI 患者。使用受试者工作特征(ROC)曲线确定 SII 的截断值以预测无复流。使用多变量逐步逻辑回归,包括单变量分析中与 NRP 有显著关联的协变量,以确定无复流的独立预测因素。

结果:ROC 曲线分析显示,SII 预测无复流的最佳截断值为 1028,敏感性和特异性分别为 79%和 70%(AUC,0.839;95%CI,0.797-0.881)。进行了 ROC 曲线比较分析,以比较 SII 与 NLR 和 PLR。多变量分析显示,SII≥1028 值(OR=6.622,95%置信区间(CI):3.802-11.627,  < .001)、入院前未使用阿司匹林(OR=0.431,95%CI:0.236-0.786,  = .006)和 CRP(OR=1.004,95%CI:1.001-1.008,  = .041)是急性 STEMI 患者直接 PCI 后发生 NRP 的独立预测因素。

结论:SII 水平与急性 STEMI 患者直接 PCI 后的 NRP 独立相关。高 SII 可能是预测这些患者 NRP 的有前途的指标。

相似文献

[1]
Systemic immune-inflammation index predicts no-reflow phenomenon after primary percutaneous coronary intervention.

Acta Cardiol. 2022-2

[2]
The Systemic Immune-Inflammation Index Predicts Impaired Myocardial Perfusion and Short-Term Mortality in ST-Segment Elevation Myocardial Infarction Patients.

Angiology. 2023-4

[3]
Assessment of systemic immune-inflammation index as an independent surrogate biomarker of no-reflow phenomenon in acute coronary syndrome patients with coronary artery bypass grafting undergoing percutaneous coronary intervention of saphenous vein graft.

Eur Rev Med Pharmacol Sci. 2023-3

[4]
Vitamin D level predicts angiographic no-reflow phenomenon after percutaneous coronary intervention in patients with ST segment elevation myocardial infarction.

Biomark Med. 2021-10

[5]
MELD-XI score predict no-reflow phenomenon and short-term mortality in patient with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

BMC Cardiovasc Disord. 2022-3-18

[6]
Relationship Between Systemic Inflammation Index and No-Reflow Phenomenon in Patients With ST-Segment Elevation Myocardial Infarction.

Angiology. 2023-4

[7]
New CHADS-VASc-HSF score predicts the no-reflow phenomenon after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction.

BMC Cardiovasc Disord. 2020-7-25

[8]
The combination of neutrophil-to-lymphocyte ratio and platelet correlation parameters in predicting the no-reflow phenomenon after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction.

Scand Cardiovasc J. 2020-12

[9]
The effect of the systemic immune-inflammatory index on the no-reflow phenomenon in patients undergoing saphenous vein intervention.

Postepy Kardiol Interwencyjnej. 2024-6

[10]
The Utility of Systemic Immune-Inflammation Index for Predicting Contrast-Induced Nephropathy in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

Cardiorenal Med. 2022

引用本文的文献

[1]
Associations between Life's Essential 8 scores and systemic immune-inflammation index among American-adult populations without cardiovascular disease.

Front Med (Lausanne). 2025-8-5

[2]
Risk Stratification in Acute Coronary Syndromes: The Systemic Immune-Inflammation Index as Prognostic Marker.

Med Sci (Basel). 2025-8-8

[3]
Prognostic impact of systemic immune inflammatory index in patients with reduced ejection fraction heart failure.

BMC Cardiovasc Disord. 2025-7-31

[4]
The efficiency of blood cell counts and inflammatory indices in prediction of need for acute kidney injury in patients with crush syndrome.

BMC Nephrol. 2025-7-26

[5]
SII as a predictor of mortality in patients with non-ST-segment elevation myocardial infarction and diabetes mellitus.

Pract Lab Med. 2025-5-16

[6]
The Predictive Value of ALBI Score for No-Reflow in Non-ST Elevation Acute Coronary Syndrome.

J Clin Med. 2025-4-28

[7]
Association of the systemic immune-inflammation index with clinical outcomes in acute myocardial infarction patients with hypertension.

BMC Immunol. 2025-2-28

[8]
Prognostic value of inflammatory markers for all-cause mortality in patients with acute myocardial infarction in the coronary care unit: a retrospective study based on MIMIC-IV database.

Front Cardiovasc Med. 2025-1-22

[9]
Evaluation of systemic immune-inflammation index and systemic inflammation response index in the differentiation of acute Ischemic stroke and transient Ischemic attack.

Malawi Med J. 2025-1-13

[10]
The systemic immune-inflammation index and systemic inflammation response index are useful for predicting mortality in patients with diabetic nephropathy.

Diabetol Metab Syndr. 2024-11-24

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索